Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms.
Jabban Y, Yacout M, Baranwal A, He R, Viswanatha D, Greipp P, Jevremovic D, Bessonen K, Foran J, Palmer J, Saliba AN, Hefazi-Torghabeh M, Begna K, Hogan WJ, Mangaonkar A, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Jabban Y, et al. Among authors: viswanatha d. Leuk Lymphoma. 2024 Nov 6:1-10. doi: 10.1080/10428194.2024.2425048. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39504138
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, Foran JM, Badar T, Mangaonkar AA, Begna KH, Gangat N, Patnaik MM, Litzow MR, Shah MV, Viswanatha DS, He R, Alkhateeb HB, Al-Kali A. Gurney M, et al. Br J Haematol. 2023 Jul;202(2):279-283. doi: 10.1111/bjh.18850. Epub 2023 May 5. Br J Haematol. 2023. PMID: 37144345
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, Greipp P, Foran J, Badar T, Murthy H, Yi CA, Palmer J, Mangaonkar AA, Patnaik MM, Litzow MR, Hogan WJ, Begna K, Gangat N, Tefferi A, Al-Kali A, Shah MV, Alkhateeb HB. Baranwal A, et al. Haematologica. 2024 Jun 1;109(6):1779-1791. doi: 10.3324/haematol.2023.284185. Haematologica. 2024. PMID: 38299584 Free PMC article.
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms.
Yacout M, Katamesh B, Jabban Y, He R, Viswanatha D, Jevremovic D, Greipp P, Bessonen K, Palmer J, Foran J, Saliba A, Hefazi-Torghabeh M, Begna K, Hogan W, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Yacout M, et al. Among authors: viswanatha d. Leukemia. 2024 Dec;38(12):2727-2730. doi: 10.1038/s41375-024-02374-9. Epub 2024 Sep 23. Leukemia. 2024. PMID: 39313565 Free PMC article. No abstract available.
Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.
Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Katamesh B, et al. Among authors: viswanatha d. Ann Hematol. 2023 Jan;102(1):211-212. doi: 10.1007/s00277-022-05016-1. Epub 2022 Nov 4. Ann Hematol. 2023. PMID: 36331566 No abstract available.
Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience.
Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonen K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, Litzow M, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Katamesh B, et al. Among authors: viswanatha d. Blood Adv. 2023 Apr 25;7(8):1351-1355. doi: 10.1182/bloodadvances.2022007937. Blood Adv. 2023. PMID: 36477202 Free PMC article. No abstract available.
Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study.
Pritzl SL, Gurney M, Badar T, Ferrer A, Lasho T, Finke C, Mangaonkar A, McCullough K, Gangat N, Fernandez J, Al-Kali A, Viswanatha D, He R, Foran J, Patnaik MM. Pritzl SL, et al. Among authors: viswanatha d. Leuk Res. 2023 Feb;125:107007. doi: 10.1016/j.leukres.2022.107007. Epub 2022 Dec 28. Leuk Res. 2023. PMID: 36586169 No abstract available.
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
Al-Kali A, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB. Al-Kali A, et al. Among authors: viswanatha d. Blood Cancer J. 2023 Apr 10;13(1):49. doi: 10.1038/s41408-023-00818-6. Blood Cancer J. 2023. PMID: 37032414 Free PMC article. No abstract available.
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T, Finke C, Alkhateeb HB, He R, Gangat N, Shah M, Tefferi A, Mangaonkar AA, Litzow MR, Ongie LJ, Chlon T, Ferrer A, Patnaik MM. Badar T, et al. Among authors: viswanatha d. Haematologica. 2023 Nov 1;108(11):3033-3043. doi: 10.3324/haematol.2023.282867. Haematologica. 2023. PMID: 37199125 Free PMC article. Review.
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML).
Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Gurney M, et al. Among authors: viswanatha d. Leukemia. 2023 Aug;37(8):1753-1756. doi: 10.1038/s41375-023-01964-3. Epub 2023 Jul 8. Leukemia. 2023. PMID: 37422593 No abstract available.
148 results